drug

ARI-ORAL

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of California Riverside at C.I. Trials, Inc.-Inland Empire
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
NCT04203056Phase 4Terminated

KOLs & investigators

1
Kenneth L Subotnik, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
trial
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
PHASE4
trial
indication
Schizophrenia
indication
Schizophreniform Disorder
indication
Schizophrenia
indication
Schizoaffective Disorder, Depressive Type
indication
KOL
Kenneth L Subotnik, PhD
KOL score —
person